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Voriconazole is the agent of choice for the treatment of invasive aspergillosis in children at least 2 years of age. The galactoman-
nan index is a routinely used diagnostic marker for invasive aspergillosis and can be useful for following the clinical response to
antifungal treatment. The aim of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) mathematical model
that links the pharmacokinetics of voriconazole with the galactomannan readout in children. Twelve children receiving vori-
conazole for treatment of proven, probable, and possible invasive fungal infections were studied. A previously published popula-
tion PKmodel was used as the Bayesian prior. The PK-PDmodel was used to estimate the average area under the concentration-
time curve (AUC) in each patient and the resultant galactomannan-time profile. The relationship between the ratio of the AUC
to the concentration of voriconazole that induced half maximal killing (AUC/EC50) and the terminal galactomannan level was
determined. The voriconazole concentration-time and galactomannan-time profiles were both highly variable. Despite this vari-
ability, the fit of the PK-PDmodel was good, enabling both the pharmacokinetics and pharmacodynamics to be described in in-
dividual children. (AUC/EC50)/15.4 predicted terminal galactomannan (P 0.003), and a ratio of>6 suggested a lower terminal
galactomannan level (P 0.07). The construction of linked PK-PDmodels is the first step in developing control software that
enables not only individualized voriconazole dosages but also individualized concentration targets to achieve suppression of
galactomannan levels in a timely and optimally precise manner. Controlling galactomannan levels is a first critical step to maxi-
mizing clinical response and survival.
Voriconazole is an extended-spectrum triazole antifungal agentwith activity againstAspergillus spp.,Candida spp.,Cryptococ-
cus neoformans, Fusarium spp., and Scedosporium apiospermum
(1). Voriconazole is licensed for use in children 12 (United
States) or 2 (Europe) years of age with invasive aspergillosis
(IA), fluconazole-resistant invasive Candida infections, or infec-
tions caused by Scedosporium spp. and Fusarium spp. and in non-
neutropenic children with candidemia (2). In all patient age
groups, voriconazole is a first-line agent for the treatment of IA (2,
3). The inter- and intraindividual variabilities in drug exposure
are high, and some of this variability can be attributed to
CYP2C19 genotype (4), impaired liver function (5), age (6), in-
flammation (7), and CYP2C19/CYP3A-interacting comedication
(8). This coupled with a reasonably detailed understanding of the
relationship between drug exposure and the probability of both
therapeutic response and toxicity has led to a recommendation to
use therapeutic drug monitoring (TDM) as an adjunct to routine
clinical use of voriconazole (9). We have recently developed soft-
ware for dosage individualization in both adults and children (10,
11). The underlying algorithms can be used to achieve desired
serum drug concentration targets in both adults and children in
an optimally precise manner.
In clinical settings, the galactomannan index is increasingly
used as a biomarker for the diagnosis of invasive aspergillosis.
According to the EORTC/MSG diagnostic criteria for invasive
fungal diseases, galactomannan can be used as a microbiological
criterion to establish a diagnosis of invasive aspergillosis (12). Ga-
lactomannan is a high-molecular-weight polysaccharide cell wall
fungal antigen that is released into the bloodstream during hyphal
growth and angioinvasion (13). Routine sequential monitoring of
serum galactomannan levels can be used for the early detection of
invasive aspergillosis (14). There is now increasing interest in us-
ing galactomannan to follow the response to antifungal therapy
(15). Such a strategy is supported by the observation that patients
with unremittingly high circulating antigen levels tend to have a
poor clinical outcome. The availability of a biomarker with both
diagnostic and prognostic significance is relatively unique in in-
fectious diseases. An understanding of galactomannan kinetics
and its response to antifungal drug concentrations provides the
possibility to provide true individualized antifungal therapy.
Here, we developed a linked pharmacokinetic-pharmacody-
namic (PK-PD) mathematical model to describe the serum phar-
macokinetics of voriconazole and the pharmacodynamics quan-
tified in terms of the circulating galactomannan levels. Sincemuch
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of the pharmacokinetic and pharmacodynamic data were neces-
sarily sparse, we buttressed the pharmacokinetics by using richer
data obtained from the early phases of drug development. Such an
approach enabled us to ensure robust estimates of the pharmaco-
kinetics, which would have otherwise been extremely difficult or
resulted in biased parameter estimates. The development of a
linked PK-PD model is a further step in the provision of true
individualized therapy where a drug is administered to control a
biomarker that is itself intricately linked to therapeutic responses
and optimal clinical outcomes.
MATERIALS AND METHODS
Patients. All patients aged18 years receiving voriconazole, with at least
one voriconazole serum concentration and galactomannan level mea-
sured, within the 9-year period from January 2005 to March 2014 were
eligible for inclusion in this study. Themedical, pharmacy, and laboratory
records at the University Medical Center Groningen were reviewed. De-
mographic, microbiological, and clinical data were collected using stan-
dardized case report forms. The voriconazole treatment regimen and se-
rum concentrations of voriconazole were also collected. Information that
could potentially influence the voriconazole serum concentrations was
identified and reviewed for potential inclusion of these serum concentra-
tions into the population PK-PD model. The EORTC/MSG criteria (12)
were used to determine the probability of invasive fungal disease for each
patient at the start of voriconazole therapy. The Medical Ethical review
board of the University Medical Center Groningen (metc 2013-491)
waived the requirement to obtain informed consent from individual pa-
tients.
TDM. All patients at the University Medical Center Groningen who
were treated with voriconazole underwent therapeutic drug monitoring
(TDM). The first sample was typically taken after 2 days, and results were
reported the same day. The therapeutic trough concentration targets
were 1 mg/liter and 6 mg/liter. Concentrations outside these values
prompted a change in dosage. There was no algorithm for dosage adjust-
ment, but typically the dose of voriconazole was increased or decreased by
30 to 50% and concentrations were remeasured after several days. Galac-
tomannan was not used to make decisions about dosage adjustment.
Voriconazole assay.The voriconazole serum concentrations were de-
termined using a validated liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) method (16). All measurements were performed
on a Thermo Fisher (San Jose, CA, USA) triple-quadrupole LC-MS/MS
with a Finnigan Surveyor LCpump and a Finnigan Surveyor autosampler,
which was set at a temperature of 20°C. The Finnigan TSQ Quantum
Discovery mass selective detector was operating in electrospray positive-
ionization mode and performed selected reaction monitoring. The ion
source spray voltage was set at 3,500 V, the sheath and auxiliary gas pres-
sures at 35 and 5 arbitrary units, respectively, and the capillary tempera-
ture at 350°C. Cyanoimipramine was used as internal standard. Analyses
were performed on a 50-mm by 2.1-mmC18 5-m analytic column (Hy-
PURITY Aquastar; Interscience Breda, The Netherlands). The column
temperature was set at 20°C. The mobile phase consisted of an aqueous
buffer (containing ammonium acetate [10 g/liter water], acetic acid [35
mg/liter water], and trifluoroacetic anhydride [2 ml/liter water]), water,
and acetonitrile. Chromatographic separationwas performed using a gra-
dient with a flow of 0.3 ml/min and a run time of 3.6 min. Sample prep-
aration was performed by protein precipitation and found to be suitable,
resulting in linear calibration curves in the range of 0.1 to 10mg/liter. The
peak height ratios of voriconazole and the internal standard were used to
calculate concentrations. This method was validated in accordance with
the Guidance for Industry Bioanalytical Method Validation of the Food
and Drug Administration. The validation showed an overall bias ranging
from 0.1 to 2.3%, a within-run coefficient of variation (CV) ranging from
1.9 to 7.8%, and a between-run CV ranging from 0.0 to 3.1%.
Galactomannan assay. The samples for the determination of the ga-
lactomannan index were measured using the Platelia Aspergillus enzyme
immunoassay (EIA) kit (Bio-Rad Laboratories) as described by the man-
ufacturer. A cutoff value for positivity in serum of 0.5 was used.
PK-PD modeling. The pharmacokinetic (i.e., serum voriconazole
concentrations) and pharmacodynamic (i.e., galactomannan values) data
from the 12 children were necessarily sparse, as they were collected as part
of routine clinical care rather than as part of a prospective clinical trial. In
addition, these sparse pharmacokinetic and pharmacodynamic data were
not necessarily optimally informative. Fitting any pharmacokineticmodel
to a limited, sparse, and nonoptimally informative data set either is not
possible or will lead to biased parameter estimates. We circumvented this
problem using a two-step process. In the first step, each of the 12 new
patients had their pharmacokinetics estimated using a previously de-
scribed population PKmodel in which the PKmodel served as the Bayes-
ian prior (11). In the second step, the Bayesian posterior estimates for each
patient’s PK parameters were fixed, and the pharmacodynamic parame-
ters were then estimated by fitting the pharmacodynamic component of
themodel to each patient’s galactomannan data. The population program
Pmetrics was used for all modeling (17).
The structural pharmacokinetic mathematical model consisted of
three differential equations that described the rate of change of the
amount of voriconazole within each compartment. A fourth equation
described the rate of change of galactomannan in the serum. These four
inhomogeneous ordinary differential equations are as follows:
dX1
dt
Ka · X1 (1)
dX2
dt
 Ka · X1 RateIV
Vmax
Km . V X2




 Kcp · X2 Kpc · X3 (3)
dX4
dt











KGMe lim · X4 (4b)
where X1, X2, and X3 are the amounts (in milligrams) in the gut, central
compartment, and peripheral compartment, respectively, and dXn/dt is
the instantaneous rate of change in the amount of drug in compartment
n 1, 2, or 3,Ka is the first-order rate constant of drug absorption after an
oral bolus dose from the gut compartment (compartment 1) to the central
serum compartment (compartment 2), RateIV is the rate of intravenous
voriconazole infusion;Vmax is themaximum rate of the enzyme activity in
metabolismof voriconazole (mg/h) andwas allometrically scaled for body
weight (kg) using the equation Vmax  Vmax0 · kg
0.75, Km is the concen-
tration of voriconazole in the central compartment at which voriconazole
clearance is half-maximal, V is the volume of the central compartment
(liters) and was also allometrically scaled as V V0 · weight, Kcp and Kpc
are the first-order rate constants connecting the central compartment and
peripheral compartment (compartment 3), X4 is the concentration of
galactomannan in the serum, KGMprod is the maximal rate of production
of galactomannan in the central compartment, POPmax is the maximal
achievable galactomannan value, KGMelim is the maximal rate of elimi-
nation of galactomannan from the central compartment, H controls the
steepness of the relationship between drug concentration and reduction
in galactomannanproduction in the central compartment, andEC50 is the
concentration of voriconazole at which half-maximal reduction in galac-
tomannan production is achieved. The oral bioavailability of voricona-
zole, F, was included because patients received voriconazole both orally
and intravenously. In Pmetrics, F is amultiplier on oral doses, and it is not
included within the differential equations.
Pharmacodynamics of Voriconazole
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Equations 1, 2, and 3 describe the rates of change of voriconazole in the
gut, central serum, and peripheral tissue kinetic compartments, respec-
tively. Equation 4 describes the rate of change of galactomannan in the
central serum kinetic compartment, and we divide this equation into two
separate terms for clarity. First, equation 4a describes the production of
galactomannan, which is limited by a maximum value and also by vori-
conazole concentrations in a sigmoidal function, such that when concen-
trations are infinite, production is zero; second, equation 4b describes the
sum of all physiologic galactomannan elimination mechanisms. A base-
line galactomannan value within compartment 4 on the day of the first
voriconazole dose was also estimated within Pmetrics, with a possible
range of 0.1 to 12, reflective of clinically observed extremes. The fit of the
mathematical model to the data was assessed using visual inspection and
linear regression of the observed versus predicted values both before and
after the Bayesian step.
Exposure-response relationships. The relationship between a tradi-
tional pharmacodynamic measures of drug exposure, such as the ratio of
the area under the concentration-time curve (AUC) to the MIC, and a
therapeutic response is often not possible to determine for invasive asper-
gillosis because the invading pathogen is usually not recovered. Therefore,
we used a new concept in these analyses. The AUC/EC50 is the ratio of the
voriconazole daily AUC to the EC50, which is the posterior Bayesian esti-
mate of the (in vivo) concentration of voriconazole required to induce
half-maximal reduction in galactomannan levels in each individual pa-
tient. Thus, the EC50 is analogous to the more traditional in vitro estimate
of drug potency, which is the MIC, but instead reflects an in vivo estimate
of potency that can be derived from the change in galactomannan and
voriconazole drug concentrations. The average daily AUC was calculated
by estimating the total fitted AUC for each patient and dividing by the
number of 24-hour treatment intervals. The average AUC circumvents
the problemof definingwhichAUC is important for treatment effect (e.g.,
the AUC following the first dose or after a week of dosing). The relation-
ship between the AUC/EC50 ratio and the final galactomannan level or
survival was explored.
RESULTS
Demographics. The demographic data for the study population
are summarized in Table 1. Fifty percent of patients had either
acute myelogenous leukemia (AML) or acute lymphoblastic leu-
kemia (ALL). The total mortality rate of the patient population
was distressingly high: 10 (83.3%) of the 12 children died. For 4 of
the 12 patients, Aspergillus spp. were recovered, and three of these
four patients died from invasive aspergillosis. In the remaining
patients, a diagnosis of probable invasive aspergillosis was estab-
lished using galactomannan.
TDMdata for voriconazole andgalactomannan.Therewere a
total of 261 and 33 measurements available for voriconazole con-
centrations and galactomannan levels from the 12 children, re-
spectively. The concentration-time profiles for these respective
readouts are shown in Fig. 1.
Population PK-PD model. The fit of the population PK-PD
model to the data was acceptable despite the extreme pharmaco-
kinetic and pharmacodynamic variability that is evident in Fig. 1.
The Bayesian posterior estimates for the pharmacokinetics and
pharmacodynamics are shown in Fig. 2 (left and right panels, re-
spectively). The pharmacodynamics (i.e., galactomannan) were
not well described using either the mean or median values for the
parameters from the population model (data not shown). There
simply was not a single set of parameter values that could be iden-
tified thatwas adequate to describe the time course of galactoman-
nan in every patient. In contrast, however, the time course of
galactomannan in each individual patient was readily described
with a high degree of precision using the Bayesian posterior esti-
mates for each patient. The heterogeneity of the different trajec-
tories of galactomannan in individual patients is evident in Fig. 1
and 3. Of note, the initial condition (i.e., the galactomannan level
at the commencement of treatment) was strikingly different be-
tween patients, potentially reflecting differences in underlying
fungal burden. Furthermore, the time course of galactomannan in
response to voriconazole therapy was also highly variable and
ranged from a prompt decrease through to persistent antigenemia
with no apparent therapeutic response.
Relationship between AUC/EC50 ratio and terminal galacto-
mannan level or survival. The relationship between the AUC/
EC50 ratio and the terminal galactomannan level is shown in Fig. 4.
Using a simple nonlinear relationship, terminal galactomannan
was strongly predicted by (AUC/EC50)/15.4 (P  0.003). As a
possible breakpoint, patients with an AUC/EC50 ratio of 6
tended to have amore consistently lower terminal galactomannan
level (P 0.07). In contrast, the AUC/EC50 ratio was not associ-
atedwith survival. Themean in thosewhodiedwas 6.1, and that in
those who survived was 7.6 (P 0.76).
DISCUSSION
Much has been written about the use of therapeutic drug moni-
toring as an indispensable adjunct to the use of voriconazole for
the treatment of invasive aspergillosis and other invasive fungal
diseases (9). There is a strong and growing evidence base to sup-
port such an assertion. Patients with serum concentrations of1
mg/liter appear to have poorer clinical outcomes and higher mor-
tality than patients with concentrations of1 mg/liter (18). Sim-
ilarly, patients with trough concentrations of 5 to 6 mg/liter
TABLE 1 Patients demographics and characteristics
Parameter Valuea
Demographics
Male gender 8 (58.3)
Age (yr) 6 (5–10)











Intravenous (mg/kg/dose) 6.1 (4.7–6.9)
Oral (mg/kg/dose) 10.2 (6.8–10.8)
Voriconazole trough concn (mg/liter) 4.1 (1.6–6.1)
Galactomannan index 1.3 (0.5–8.1)
a Values are number (percentage) of patients or median (interquartile range).
b Other malignancies included non-Hodgkin lymphoma, immunodeficiency,
osteosarcoma, Hodgkin lymphoma, and rhabdomyosarcoma.
c Based on the opinion of the attending physician of the Children’s Oncology ward at
the beginning of the admission. Patients were classified as having possible invasive
aspergillosis if the galactomannan was initially negative when voriconazole was
commenced but later became positive, at which time the diagnostic classification was
upgraded to probable.
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have a higher probability of having hepatotoxicity and confusion
(18, 19). The case for routine TDM is further enhanced by the
extreme pharmacokinetic variability that is characteristic of vori-
conazole and clearly evident in this study. The question raised by
these analyses is whether TDM and dosage adjustment to achieve
desired serum drug concentrations constitute the ultimate solu-
tion for using voriconazole and whether they constitute “true in-
dividualized therapy.”
The current strategy for TDM of voriconazole (or any other
antimicrobial) is quite inconsistent with respect to individualiza-
tion. The case for quantifying and controlling individual pharma-
cokinetic variability through dose modification has been made
time and again bymanypeople (including us).Wehave gone as far
as use the information stored within population pharmacokinetic
models to construct software that can be used for voriconazole
dosage individualization in adults and children (10, 11). Impor-
tantly, the use of such software demands that the clinician define a
drug concentration target that is deemed to have a high probabil-
ity of therapeutic success and a low probability of toxicity. All the
therapeutic targets that are used and cited in various guidelines are
derived from large populations of patients, which are in effect
“average” values. Such an approach is counter to all notions of
individualized therapy and in fact is “one-size-fits-all” target se-
lection. A significant advance that is enabled by the use of bio-
markers such as galactomannan is the prospect of achieving true
individualized target concentrations based on measured pharma-
codynamics. Some patients will need more drug exposure, while
others will need less. A different way of expressing this idea is that
both the pharmacokinetics and pharmacodynamics are different
frompatient to patient but need to be optimized for an individual.
A priori the trajectory of the voriconazole concentration-time
profile or the galactomannan in an individual patient is unknow-
able. Variability in both pharmacokinetics and pharmacodynam-
ics contributes to both good and poor clinical outcomes, and the
achievement of optimal clinical outcomes requires control of
both.
Figure 3 is particularly illustrative of the many challenges fac-
ing clinicians who are treating children with invasive fungal dis-
eases. First, the pharmacokinetics of voriconazole are highly vari-
able, as previously described by us and many others. Second, and
perhapsmore important, is the observation that the pharmacody-
namics are also highly variable. There is no way of predicting
which path (galactomannan trajectory) an individual patient will
follow once voriconazole is started. Results from phase II and III
clinical studies (20, 21) suggest that on average a satisfactory clin-
ical response will be obtained when a fixed dosing strategy is used,
but that does not provide any guarantee that the patient has been
dosed such that the likelihood of a response is above average.
Galactomannan provides a real-time indication of the patient’s
individual response to voriconazole and whether a therapeutic
response is being achieved or not. It is possible to react to changes
in galactomannan directly rather than just to the voriconazole
concentration. Consider the differences in galactomannan re-
sponses between patient 177 and patient 180 in Fig. 3. Both pa-
tients achieve comparable voriconazole serum concentrations in
the first days of therapy, but their pharmacodynamics are com-
FIG 1 Voriconazole concentration-time profiles (A) and galactomannan-time profiles (B) for 12 pediatric patients who had concomitantly collected galacto-
mannan and serum voriconazole concentration data. The samplings of voriconazole and galactomannan were not linked; hence, voriconazole serum concen-
tration data were available after galactomannan sampling had stopped.
FIG2 Observed versus predicted values after the Bayesian step for voriconazole serumconcentrations (left panel) and for galactomannan (right panel). The solid
lines are the linear regressions of the observed-predicted concentrations.
Pharmacodynamics of Voriconazole
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pletely different for reasons that may not be immediately obvious.
Patient 177 appears not to be responding to voriconazole and
should have the dose increased, the drug changed to an alternative
agent, or a second antifungal agent added. Instead, the dosage was
reduced, probably because the upper TDM target was exceeded
(again, this value is derived from a population of patients). How-
ever, the population value may not have been appropriate for that
patient. This suboptimal regimen resulted in sustained galacto-
mannan antigenemia, and the patient ultimately died. In contrast,
patient 180 achieved a sustained response in their galactomannan
trajectory (despite having voriconazole concentrations ordinarily
considered to be associated with a higher probability of toxicity)
and ultimately survived.
We do not claim that this is an ideal data set. The data are
sparse and were not collected at optimally informative times. Fit-
ting was difficult and required a preexisting population PKmodel
that could be used as a Bayesian prior. Despite some limitations, it
is remarkable that the PK-PD mathematical model fits any of the
data, given that they were collected in routine clinical settings.
Importantly, however, there is an acceptable fit of themodel to the
data only after the Bayesian step. In this regard, fitting models to
galactomannan data is similar to fitting mathematical models to
drug resistance data, where population fits are often notoriously
bad. The reason for this is obvious following a brief inspection of
the raw data in Fig. 1B. The galactomannan data are nonmono-
tonic. Some profiles rise unexpectedly, while others fall. Such het-
erogeneity in responsemakes it nearly impossible to derive a single
set of parameter values that account for all the data in a reasonably
unbiased yet satisfactorily precise manner. We could have per-
formed Monte Carlo simulation on the Bayesian posterior esti-
mates to explore the impact of both pharmacokinetic and phar-
macodynamic variability on the therapeutic outcome, but we
ultimately decided that this would have produced unreliable re-
sults given the paucity of data (some patients have only one or two
observations). However, this could easily be done in the future
with larger and more comprehensive data sets.
The AUC/EC50 ratio is a pharmacodynamic index that may
be helpful in future studies of invasive aspergillosis. While the
FIG 3 Serum voriconazole concentration-time profiles (solid black lines) and serum galactomannan-time profiles (gray lines) from the 12 children with
concomitant PK and PD data. The raw data for voriconazole (black circles) and galactomannan (gray circles) are shown. In each case, the model fit is from the
Bayesian posterior estimate. Only patients 159 and 180 survived.
Huurneman et al.
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EC50 requires at least one measured voriconazole level and ga-
lactomannan level in a patient and requires some PK-PD mod-
eling expertise, it captures and quantifies much of the pharma-
codynamic variability that is evident in this study. Thus, the
AUC/EC50 ratio provides an understanding of the therapeutic
response in terms of drug exposure (AUC) as well as the phar-
macodynamics. A high estimate for EC50 may be caused by
factors such as a high fungal burden, the presence of antifungal
resistance mechanisms, a delay in the initiation of antifungal
therapy, infection within sanctuary sites, and profound immu-
nosuppression. In this way, we view it as potentially superior to
the in vitro MIC, which does not account for the clinical ther-
apeutic environment within a patient. The AUC/EC50 ratio is a
fully individualized in vivo estimate of drug potency, and it
significantly predicted terminal galactomannan levels, even in
this small study. It did not predict survival, but the majority of
this cohort died from a range of causes, including the underly-
ing disease. Furthermore, terminal galactomannan is likely a
more objective reflection of in vivo voriconazole efficacy than
survival, which is multifactorial, especially in these kinds of
patients with complex underlying medical problems.
The next steps are clear. Larger, richer data sets that contain opti-
mally informative sampling for both voriconazole and galactoman-
nan will enable the construction of more robust pharmacokinetic-
pharmacodynamic mathematical models. These models will form
the basis of dual-output stochastic controllers where a clinician
has the option to individualize dosing to control the serum
drug concentrations, the circulating biomarker, or both. Such
an advance represents a further critical step toward the provi-
sion of true individualized therapy, which is surely the ultimate
goal of all clinicians treating any patient with a life-threatening
invasive fungal infection. Such an approach is one key advance
for better care of immunocompromised patients who usually
have multiple comorbidities. Moreover, as circulating bio-
markers are developed for other diseases, this approach can be
applied to a wider range of infections.
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